V. Bibliographie-1, R. Dhar, L. Stitt, and A. Hahn, The morbidity and outcome of patients with Guillain-Barré syndrome admitted to the intensive care unit, J Neurol Sci, vol.264, pp.121-129, 2008.

T. Sharshar, S. Chevret, F. Bourdain, and J. Raphaël, Early predictors of mechanical ventilation in Guillain-Barr?? syndrome, Critical Care Medicine, vol.31, issue.1, pp.278-83, 2003.
DOI : 10.1097/00003246-200301000-00044

J. Rees, R. Thompson, N. Smeeton, and R. Hughes, Epidemiological study of Guillain-Barre syndrome in south east England, Journal of Neurology, Neurosurgery & Psychiatry, vol.64, issue.1, pp.74-81, 1998.
DOI : 10.1136/jnnp.64.1.74

A. Chomel, De l'épidémie actuellement régnante à Paris, Journal Hebdomadaire de Médecine. Paris, pp.331-339, 1828.

. Landry-0, Note sur la paralysie ascendante aiguë. Gaz Hebd Med Chir, pp.472-88, 1859.

B. Schott, Histoire du syndrome de Guillain et Barré, Paris, vol.12, 1982.

G. Guillain, J. Barré, and A. Strohl, Sur un syndrome de radiculonevrite avec hyperalbuminose du liquide cephalo-rachidien sans reaction cellulaire. Remarques sur les caracteres cliniques et graphiques des reflexes tendineaux, 1916.

A. Asbury, Diagnostic considerations in Guillain-Barré syndrome, Ann Neurol, vol.9, 1981.

A. Asbury and D. Cornblath, Assessment of current diagnostic criteria for Guillain-Barr??? syndrome, Annals of Neurology, vol.10, issue.S1, pp.21-25, 1990.
DOI : 10.1002/ana.410270707

R. Hughes and D. Cornblath, Guillain-Barré syndrome. The Lancet, pp.1653-66, 2005.

T. Sharshar, S. Siami, and D. Orlikowski, Ce malade est-il atteint d'un syndrome de Guillain-Barré ? Réanimation, pp.504-514, 2007.

A. Bersano, M. Carpo, S. Allaria, D. Franciotta, A. Citterio et al., Long term disability and social status change after Guillain???Barr?? syndrome, Journal of Neurology, vol.51, issue.2, pp.214-222, 2006.
DOI : 10.1212/WNL.59.2.282

L. Visser, F. Van-der-meché, J. Meulstee, P. Van-doorn, R. Van-koningsveld et al., Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome. Dutch Guillain-Barré study group Distinguishing acute-onset CIDP from Guillain- Barré syndrome with treatment related fluctuations Assessment of autonomic dysfunction in Guillain-Barré syndrome and its prognostic implications, 242?4. 14. Ruts L138?40. 15. Singh NK, pp.101-106, 1987.

J. Winer, R. Hughes, and O. C. , A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value., Journal of Neurology, Neurosurgery & Psychiatry, vol.51, issue.5, pp.605-617, 1988.
DOI : 10.1136/jnnp.51.5.605

J. Winer and R. Hughes, Identification of patients at risk of arrhythmia in the Guillain-Barré syndrome, Q J Med, vol.68, pp.735-744, 1988.

D. Zochodne, Autonomic involvement in Guillain-Barre syndrome: A review, Muscle & Nerve, vol.461, issue.10, pp.1145-55, 1994.
DOI : 10.1536/ihj.26.593

A. Ropper, B. R. Shahani, U. Einarsson, J. De-pedro-cuesta, W. Holmqvist et al., Pain in Guillain-Barré syndrome Swedish Epidemiological Study Group. Impairment in Guillain-Barré syndrome during the first 2 years after onset: a prospective study, Arch Neurol. J Neurol Sci, vol.41227, pp.131-139, 1984.

B. Pentland, S. Donald, J. Drenthen, J. Jongen, W. Hop et al., Pain in the Guillain-Barré syndrome: a clinical review Pain in Guillain- Barre syndrome: a long-term follow-up study Cutaneous innervation in Guillain-Barré syndrome: pathology and clinical correlations, 159?64. 23. Ruts L1439?47. 24. Pan C, pp.386-97, 1994.

J. Liu, L. Wang, and E. Mcnicol, Pharmacological treatment for pain in Guillain-Barré syndrome, Cochrane Database Syst Rev, vol.10, 2013.

T. Rekand, A. Gramstad, and C. Vedeler, Fatigue, pain and muscle weakness are frequent after Guillain-Barr?? syndrome and poliomyelitis, Journal of Neurology, vol.63, issue.3, pp.349-54, 2009.
DOI : 10.1212/01.WNL.0000148589.87107.9C

M. Odaka, Y. N. Yamada, M. Koga, M. Takemi, T. Hirata et al., Bickerstaff???s brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain???Barr?? syndrome, Brain, vol.126, issue.10, pp.2279-90, 2003.
DOI : 10.1002/ana.1012

J. Overell, S. Hsieh, M. Odaka, Y. N. Willison, and H. , Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders. Cochrane Database Syst Rev, 2007.

Z. Islam, B. Jacobs, M. Islam, Q. Mohammad, S. Diorditsa et al., High incidence of Guillain-Barre syndrome in children Gastroenteritis-associated Guillain-Barré syndrome on the Caribbean island Curaçao, Bangladesh. Emerg Infect Dis. Neurology, vol.1756, issue.30, pp.1467-72, 2001.

M. Rocha, S. Brucki, A. Carvalho, S. Lima, and U. , Epidemiologic features of Guillain-Barr?? syndrome in S??o Paulo, Brazil, Arquivos de Neuro-Psiquiatria, vol.64, issue.Suppl1, pp.33-40, 2004.
DOI : 10.1136/jnnp.64.1.74

J. Sejvar, A. Baughman, M. Wise, and O. Morgan, Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis123?33. 33. McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review, Neuroepidemiology. Neuroepidemiology, vol.3632, pp.150-63, 2009.

P. Van-doorn, L. Ruts, and B. Jacobs, Clinical features, pathogenesis, and treatment of Guillain-Barr?? syndrome, The Lancet Neurology, vol.7, issue.10, pp.939-50, 2008.
DOI : 10.1016/S1474-4422(08)70215-1

R. Hadden, D. Cornblath, R. Hughes, J. Zielasek, H. Hartung et al., Electrophysiological classification of guillain-barr?? syndrome: Clinical associations and outcome, Annals of Neurology, vol.18, issue.Suppl, pp.780-788, 1998.
DOI : 10.1007/BF00792612

Z. Islam, B. Jacobs, A. Van-belkum, Q. Mohammad, M. Islam et al., Axonal variant of Guillain-Barre syndrome associated with Campylobacter infection in Bangladesh, Neurology, vol.74, issue.7, pp.581-588, 2010.
DOI : 10.1212/WNL.0b013e3181cff735

A. Hiraga, M. Mori, K. Ogawara, S. Kojima, T. Kanesaka et al., Recovery patterns and long term prognosis for axonal Guillain-Barre syndrome, Journal of Neurology, Neurosurgery & Psychiatry, vol.76, issue.5, pp.719-741, 2005.
DOI : 10.1136/jnnp.2004.051136

URL : http://jnnp.bmj.com/content/jnnp/76/5/719.full.pdf

T. Ho, B. Mishu, C. Li, C. Gao, D. Cornblath et al., infection and anti-glycolipid antibodies, Brain, vol.118, issue.3, pp.597-605, 1995.
DOI : 10.1093/brain/118.3.597

D. Sang, Q. Chen, X. Liu, H. Qu, D. Wei et al., Fc receptor like 3 in Chinese patients of Han nationality with Guillain???Barr?? syndrome, Journal of Neuroimmunology, vol.246, issue.1-2, pp.65-73, 2012.
DOI : 10.1016/j.jneuroim.2012.03.006

B. Jacobs, P. Van-doorn, P. Schmitz, A. Tio-gillen, P. Herbrink et al., infections and anti-GM1 antibodies in guillain-barr?? syndrome, Annals of Neurology, vol.24, issue.suppl, pp.181-188, 1996.
DOI : 10.1016/0140-6736(90)91234-2

B. Jacobs, P. Rothbarth, F. Van-der-meché, P. Herbrink, P. Schmitz et al., The spectrum of antecedent infections in Guillain-Barre syndrome: A case-control study, Neurology, vol.51, issue.4, pp.1110-1115, 1998.
DOI : 10.1212/WNL.51.4.1110

N. Yuki and H. Hartung, Guillain???Barr?? Syndrome, New England Journal of Medicine, vol.366, issue.24, pp.2294-304, 2012.
DOI : 10.1056/NEJMra1114525

B. Mishu and M. Blaser, Role of Infection Due to Campylobacter jejuni in the Initiation of Guillain-Barre Syndrome, Clinical Infectious Diseases, vol.17, issue.1, pp.104-112, 1993.
DOI : 10.1093/clinids/17.1.104

M. Harun-or-rashid, S. Akbar, K. Takahashi, M. Al-mahtab, M. Khan et al., Epidemiological and molecular analyses of a non-seasonal outbreak of acute icteric hepatitis E in Bangladesh, Journal of Medical Virology, vol.341, issue.8, pp.1369-76, 2013.
DOI : 10.1016/0140-6736(93)90599-C

X. Wu, K. Liu, and H. Zhang, Guillain???Barr?? syndrome and encephalitis/encephalopathy associated with acute severe hepatitis E infection, Neurological Sciences, vol.42, issue.1, 2014.
DOI : 10.2169/internalmedicine.42.220

T. Comont, D. Bonnet, N. Sigur, A. Gerdelat, F. Legrand-abravanel et al., Acute hepatitis E infection associated with Guillain-Barré syndrome in an immunocompetent patient. Rev Médecine Interne Fondée Par Société Natl Francaise Médecine Interne Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis, Nat Rev Neurol, vol.35, 2014.

H. Marcus, Die Influenza und das Nervensystem Studie w??hrend der Epidemie in Schweden 1918???1919, Zeitschrift f??r die gesamte Neurologie und Psychiatrie, vol.54, issue.1, pp.166-224, 1918.
DOI : 10.1007/BF02866117

G. Howland, The Nervous Conditions Associated with Influenza, Can Med Assoc J, vol.9, pp.727-758, 1919.

H. Lehmann, H. Hartung, B. Kieseier, and R. Hughes, Guillain-Barr?? syndrome after exposure to influenza virus, The Lancet Infectious Diseases, vol.10, issue.9, pp.643-51, 2010.
DOI : 10.1016/S1473-3099(10)70140-7

J. Stowe, N. Andrews, L. Wise, and E. Miller, Investigation of the Temporal Association of Guillain-Barre Syndrome With Influenza Vaccine and Influenzalike Illness Using the United Kingdom General Practice Research Database, American Journal of Epidemiology, vol.166, issue.20, pp.382-390, 2009.
DOI : 10.1001/archinte.166.20.2217

C. Vellozzi, S. Iqbal, K. Broder, H. Yacoub, H. Khan et al., Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence Clin Infect Dis Off Publ Infect Dis Soc Am Guillain-Barré syndrome after influenza vaccination in the United States, a report from the CDC/FDA vaccine adverse event reporting system, J Clin Neuromuscul Dis, vol.5814, pp.66-71, 1990.

L. Schonberger, D. Bregman, J. Sullivan-bolyai, R. Keenlyside, D. Ziegler et al., Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, Am J Epidemiol, vol.110, pp.1976-1977105, 1979.

E. Hurwitz, L. Schonberger, D. Nelson, R. Holman, M. Viray et al., Guillain-Barré syndrome and the 1978- 1979 influenza vaccine Guillain-Barre syndrome during the 2009-2010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million Americans, N Engl J Med. Am J Epidemiol, vol.304175, pp.1110-1119, 1981.

J. Tuttle, R. Chen, H. Rantala, J. Cherry, P. Rhodes et al., The risk of Guillain-Barr?? syndrome after tetanus-toxoid-containing vaccines in adults and children in the United States., American Journal of Public Health, vol.87, issue.12, pp.2045-2053, 1997.
DOI : 10.2105/AJPH.87.12.2045

R. Hughes, J. Rees, N. Smeeton, and J. Winer, Vaccines and Guillain-Barre syndrome, BMJ, vol.312, issue.7044, pp.1475-1481, 1996.
DOI : 10.1136/bmj.312.7044.1475d

S. Romio, D. Weibel, J. Dieleman, H. Olberg, C. De-vries et al., Guillain-Barr?? Syndrome and Adjuvanted Pandemic Influenza A (H1N1) 2009 Vaccines: A Multinational Self-Controlled Case Series in Europe, PLoS ONE, vol.169, issue.1, 2014.
DOI : 10.1371/journal.pone.0082222.t005

S. Greene, M. Rett, C. Vellozzi, L. Li, M. Kulldorff et al., Guillain-Barr?? Syndrome, Influenza Vaccination, and Antecedent Respiratory and Gastrointestinal Infections: A Case-Centered Analysis in the Vaccine Safety Datalink, 2009???2011, PLoS ONE, vol.30, issue.6, p.67185, 2009.
DOI : 10.1371/journal.pone.0067185.s004

E. Israeli, N. Agmon-levin, M. Blank, J. Chapman, and Y. Shoenfeld, Guillain???Barr?? Syndrome???A Classical Autoimmune Disease Triggered by Infection or Vaccination, 121?30. 64. Nakayama T, Onoda K. Vaccine adverse events reported in post-marketing study of the Kitasato Institute from, pp.570-576, 1994.
DOI : 10.1001/archinte.166.20.2217

A. Ropper, Intensive care of acute Guillain-Barré syndrome, Can J Neurol Sci J Can Sci Neurol, vol.21, pp.23-30, 1994.

D. Orlikowski, T. Sharshar, R. Porcher, D. Annane, J. Raphael et al., Prognosis and risk factors of early onset pneumonia in ventilated patients with Guillain???Barr?? syndrome, Intensive Care Medicine, vol.32, issue.Suppl, 2006.
DOI : 10.1164/ajrccm.159.6.9808030

Y. Rajabally and A. Uncini, Outcome and its predictors in Guillain???Barr?? syndrome, Journal of Neurology, Neurosurgery & Psychiatry, vol.83, issue.7, pp.711-719, 2012.
DOI : 10.1136/jnnp-2011-301882

N. Mossberg, M. Nordin, C. Movitz, S. Nilsson, K. Hellstrand et al., The recurrent Guillain-Barré syndrome: a long-term population-based study154?61. 69. Lawn ND, Wijdicks EF. Fatal Guillain-Barré syndrome Mortality in Guillain-Barré syndrome, Medical Research Council. Aids to the examination of the peripheral nervous system. Her Majesty's Stationery Office, pp.1650-1654, 1981.

A. Compston, Aids to the Investigation of Peripheral Nerve Injuries. Medical Research Council: Nerve Injuries Research Committee. His Majesty's Stationery Office: 1942; pp. 48 (iii) and 74 figures and 7 diagrams; with Aids to the Examination of the Peripheral Nervous System. By Michael O'Brien for the Guarantors of Brain. Saunders Elsevier: 2010; pp. [8] 64 and 94 Figures, Brain, vol.133, issue.10, pp.2838-2882, 2010.
DOI : 10.1093/brain/awq270

R. Hughes, A. Swan, and P. Van-doorn, Intravenous immunoglobulin for Guillain-Barré syndrome, Cochrane Database Syst Rev, vol.7, 2012.

J. Raphaël, S. Chevret, R. Hughes, and D. Annane, Plasma exchange for Guillain-Barré syndrome, Cochrane Database Syst Rev, vol.7, 2012.

S. Van-nes, E. Vanhoutte, C. Faber, M. Garssen, P. Van-doorn et al., Improving fatigue assessment in immune-mediated neuropathies: the modified Rasch-built fatigue severity scale, Journal of the Peripheral Nervous System, vol.49, issue.4, pp.268-78, 2009.
DOI : 10.1212/WNL.53.8.1648

S. Van-nes, E. Vanhoutte, P. Van-doorn, M. Hermans, M. Bakkers et al., Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies, Neurology, vol.76, issue.4, pp.337-382, 2011.
DOI : 10.1212/WNL.0b013e318208824b

E. Vanhoutte, C. Faber, and I. Merkies, 196th ENMC international workshop: Outcome measures in inflammatory peripheral neuropathies 8???10 February 2013, Naarden, The Netherlands, Neuromuscular Disorders, vol.23, issue.11, pp.924-957, 2013.
DOI : 10.1016/j.nmd.2013.06.006

R. Hughes, R. Hadden, J. Rees, and A. Swan, The Italian Guillain-Barre Study Group. The prognosis and main prognostic indicators of Guillain-Barre syndrome: a multicentre prospective study of 297 patients, Brain, vol.121, issue.4, pp.767-776, 1998.
DOI : 10.1093/brain/121.4.767

B. Cheng, W. Chang, J. Chen, E. Chee, C. Huang et al., Long-term prognosis for Guillain-Barr?? syndrome: Evaluation of prognostic factors and clinical experience of automated double filtration plasmapheresis, Journal of Clinical Apheresis, vol.119, issue.4, pp.175-80, 2003.
DOI : 10.1093/brain/119.6.2053

A. Chiò, D. Cocito, M. Leone, M. Giordana, G. Mora et al., Guillain-Barré syndrome: a prospective, population-based incidence and outcome survey A clinical prognostic scoring system for Guillain-Barré syndrome Early recognition of poor prognosis in Guillain-Barre syndrome, Neurology. Lancet Neurol. Neurology, vol.6676, issue.82, pp.968-75, 2003.

R. Hadden, H. Karch, H. Hartung, J. Zielasek, B. Weissbrich et al., Preceding infections, immune factors, and outcome in Guillain-Barre syndrome, Neurology, vol.56, issue.6, pp.758-65, 2001.
DOI : 10.1212/WNL.56.6.758

M. Durand, R. Porcher, D. Orlikowski, J. Aboab, C. Devaux et al., Clinical and electrophysiological predictors of respiratory failure in Guillain-Barr?? syndrome: a prospective study, The Lancet Neurology, vol.5, issue.12, pp.1021-1029, 2006.
DOI : 10.1016/S1474-4422(06)70603-2

L. Visser, P. Schmitz, J. Meulstee, P. Van-doorn, and F. Van-der-meché, Prognostic factors of Guillain-Barre syndrome after intravenous immunoglobulin or plasma exchange, Neurology, vol.53, issue.3, pp.598-604, 1999.
DOI : 10.1212/WNL.53.3.598

D. Fletcher, N. Lawn, T. Wolter, and E. Wijdicks, Long-term outcome in patients with Guillain-Barre syndrome requiring mechanical ventilation, Neurology, vol.54, issue.12, pp.2311-2316, 2000.
DOI : 10.1212/WNL.54.12.2311

S. Kuwabara, M. Mori, K. Ogawara, T. Hattori, Y. N. Mellits et al., Indicators of rapid clinical recovery in Guillain-Barré syndrome Motor conduction studies in Guillain-Barré syndrome: description and prognostic value, J Neurol Neurosurg Psychiatry. Ann Neurol, vol.7023, pp.354-363, 1988.

C. Inflammatory-neuropathy, IGOS International GBS Outcome Study: prognosis tool, 2015.

R. Henderson, N. Lawn, D. Fletcher, R. Mcclelland, and E. Wijdicks, The morbidity of Guillain-Barre syndrome admitted to the intensive care unit, Neurology, vol.60, issue.1, pp.17-21, 2003.
DOI : 10.1212/01.WNL.0000035640.84053.5B

A. Alshekhlee, Z. Hussain, B. Sultan, and B. Katirji, Guillain-Barre syndrome: Incidence and mortality rates in US hospitals, Neurology, vol.70, issue.18, pp.1608-1621, 2008.
DOI : 10.1212/01.wnl.0000310983.38724.d4

A. Asbury, B. Arnason, and R. Adams, THE INFLAMMATORY LESION IN IDIOPATHIC POLYNEURITIS, Medicine, vol.48, issue.3, pp.173-215, 1969.
DOI : 10.1097/00005792-196905000-00001

J. Prineas, Pathology of the Guillain-Barr??? syndrome, Annals of Neurology, vol.27, issue.S1, pp.6-19, 1981.
DOI : 10.1001/archneur.1969.00480150059008

G. Mckhann, D. Cornblath, J. Griffin, T. Ho, C. Li et al., Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China Pathology of the motor-sensory axonal Guillain-Barré syndrome, 333?42. 95, pp.17-28, 1993.

C. Linington, S. Izumo, M. Suzuki, K. Uyemura, R. Meyermann et al., A permanent rat T cell line that mediates experimental allergic neuritis in the Lewis rat in vivo, J Immunol Baltim Md, vol.133, 1950.

W. Taylor and R. Hughes, T lymphocyte activation antigens in Guillain-Barr?? syndrome and chronic idiopathic demyelinating polyradiculoneuropathy, Journal of Neuroimmunology, vol.24, issue.1-2, pp.33-42, 1989.
DOI : 10.1016/0165-5728(89)90095-7

C. Vedeler, R. Matre, and H. Nyland, Class and IgG subclass distribution of antibodies against peripheral nerve myelin in sera from patients with inflammatory demyelinating polyradiculoneuropathy, Acta Neurologica Scandinavica, vol.76, issue.suppl 1, pp.401-408, 1988.
DOI : 10.1212/WNL.35.10.1420

C. Dahle, C. Ekerfelt, M. Vrethem, M. Samuelsson, and J. Ernerudh, T helper type 2 like cytokine responses to peptides from P0 and P2 myelin proteins during the recovery phase of Guillain-Barr?? syndrome, Journal of the Neurological Sciences, vol.153, issue.1, pp.54-60, 1997.
DOI : 10.1016/S0022-510X(97)00178-0

P. Csurhes, A. Sullivan, K. Green, M. Pender, and P. Mccombe, T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy, Journal of Neurology, Neurosurgery & Psychiatry, vol.76, issue.10, pp.1431-1440, 2005.
DOI : 10.1136/jnnp.2004.052282

A. Ben-smith, J. Goodall, J. Gaston, and J. Winer, Stimulation of peripheral blood lymphocytes with Campylobacter jejuni generates a gammadelta T cell response in patients with Guillain-Barre syndrome, Clinical and Experimental Immunology, vol.109, issue.1, pp.121-127, 1997.
DOI : 10.1046/j.1365-2249.1997.4221318.x

A. Khalili-shirazi, N. Gregson, and R. Hughes, CD1 expression in human peripheral nerve of GBS patients, Biochemical Society Transactions, vol.25, issue.2, p.172, 1997.
DOI : 10.1042/bst025172s

C. Caporale, A. Uncini, and A. Giovannini, Susceptibility to Guillain???Barr?? syndrome is associated to polymorphisms of CD1 genes, Journal of Neuroimmunology, vol.177, issue.1-2, pp.201-202193, 2007.
DOI : 10.1016/j.jneuroim.2006.05.018

M. Kuijf, K. Geleijns, N. Ennaji, W. Van-rijs, P. Van-doorn et al., Susceptibility to Guillain???Barr?? syndrome is not associated with CD1A and CD1E gene polymorphisms, Journal of Neuroimmunology, vol.205, issue.1-2, pp.110-112, 2008.
DOI : 10.1016/j.jneuroim.2008.08.013

A. Chiba, S. Kusunoki, H. Obata, R. Machinami, and I. Kanazawa, Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome, Brain Research, vol.745, issue.1-2, pp.32-38, 1997.
DOI : 10.1016/S0006-8993(96)01123-7

R. Quarles, A. Ilyas, and H. Willison, Antibodies to glycolipids in demyelinating diseases of the human peripheral nervous system, Chemistry and Physics of Lipids, vol.42, issue.1-3, pp.235-283, 1986.
DOI : 10.1016/0009-3084(86)90055-1

S. Kuwabara and Y. N. , Axonal Guillain-Barr?? syndrome: concepts and controversies, The Lancet Neurology, vol.12, issue.12, pp.1180-1188, 2013.
DOI : 10.1016/S1474-4422(13)70215-1

C. Hafer-macko, S. Hsieh, C. Li, T. Ho, K. Sheikh et al., Acute motor axonal neuropathy: An antibody-mediated attack on axolemma, Annals of Neurology, vol.99, issue.4, pp.635-679, 1996.
DOI : 10.1212/WNL.43.4.809

C. Hafer-macko, K. Sheikh, C. Li, T. Ho, D. Cornblath et al., Immune attack on the schwann cell surface in acute inflammatory demyelinating polyneuropathy, Annals of Neurology, vol.263, issue.5, pp.625-660, 1996.
DOI : 10.1212/WNL.37.2.242

H. Willison and Y. N. , Peripheral neuropathies and anti-glycolipid antibodies, Brain, vol.125, issue.12, pp.2591-625, 2002.
DOI : 10.1093/brain/awf272

URL : https://academic.oup.com/brain/article-pdf/125/12/2591/1115267/awf272.pdf

K. Kaida, D. Morita, M. Kanzaki, K. Kamakura, K. Motoyoshi et al., Anti-ganglioside complex antibodies associated with severe disability in GBS, Journal of Neuroimmunology, vol.182, issue.1-2, pp.212-220, 2007.
DOI : 10.1016/j.jneuroim.2006.09.013

N. Yuki, Anti-ganglioside antibody and neuropathy: review of our research, J Peripher Nerv Syst JPNS, vol.3, pp.3-18, 1998.

C. Ang, Y. N. Jacobs, B. Koga, M. Van-doorn, P. Schmitz et al., Rapidly progressive, predominantly motor Guillain-Barre syndrome with anti-GalNAc-GD1a antibodies, Neurology, vol.53, issue.9, pp.2122-2129, 1999.
DOI : 10.1212/WNL.53.9.2122

A. Chiba, S. Kusunoki, T. Shimizu, and I. Kanazawa, Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome, Annals of Neurology, vol.44, issue.6, pp.677-686, 1992.
DOI : 10.1212/WNL.40.12.1900

H. Willison, J. Veitch, G. Paterson, and P. Kennedy, Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside., Journal of Neurology, Neurosurgery & Psychiatry, vol.56, issue.2, pp.204-210, 1993.
DOI : 10.1136/jnnp.56.2.204

S. Kusunoki, M. Iwamori, A. Chiba, S. Hitoshi, M. Arita et al., GM1b is a new member of antigen for serum antibody in Guillain-Barre syndrome, Neurology, vol.47, issue.1, pp.237-279, 1996.
DOI : 10.1212/WNL.47.1.237

H. Willison, The immunobiology of Guillain-Barre syndromes, Journal of the Peripheral Nervous System, vol.53, issue.2, pp.94-112, 2005.
DOI : 10.1007/s281-001-8167-7

N. Yuki, S. Sato, S. Tsuji, T. Ohsawa, and T. Miyatake, Frequent presence of anti-GQ1b antibody in Fisher's syndrome, Neurology, vol.43, issue.2, pp.414-421, 1993.
DOI : 10.1212/WNL.43.2.414

N. Yuki, T. Taki, and S. Handa, Antibody to Ga1NAc-GD1a and Ga1NAc-GM1b in Guillain???Barr?? syndrome subsequent to Campylobacter jejuni enteritis, Journal of Neuroimmunology, vol.71, issue.1-2, pp.155-61, 1996.
DOI : 10.1016/S0165-5728(96)00142-7

N. Yuki, C. Ang, M. Koga, B. Jacobs, P. Van-doorn et al., Clinical features and response to treatment in Guillain-Barr??? syndrome associated with antibodies to GM1b ganglioside, Annals of Neurology, vol.21, issue.3, pp.314-335, 2000.
DOI : 10.1212/WNL.53.9.2122

N. Yuki and S. Kuwabara, Axonal Guillain-Barr?? syndrome: carbohydrate mimicry and pathophysiology, Journal of the Peripheral Nervous System, vol.40, issue.4, pp.238-287, 2007.
DOI : 10.1073/pnas.0402391101

R. Ledeen, Gangliosides of the neuron, Trends in Neurosciences, vol.8, pp.169-74, 1985.
DOI : 10.1016/0166-2236(85)90064-5

M. Roberts, H. Willison, A. Vincent, and J. Newsom-davis, Serum factor in Miller-Fisher variant of Guillain-Barr?? syndrome and neurotransmitter release, The Lancet, vol.343, issue.8895, pp.454-459, 1994.
DOI : 10.1016/S0140-6736(94)92694-8

C. Goodyear, O. Hanlon, G. Plomp, J. Wagner, E. Morrison et al., Monoclonal antibodies raised against Guillain-Barr?? syndrome???associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations, Journal of Clinical Investigation, vol.104, issue.6, pp.697-708, 1999.
DOI : 10.1172/JCI6837

J. Plomp, P. Molenaar, O. Hanlon, G. Jacobs, B. Veitch et al., Miller Fisher anti-GQ1b antibodies: ?-Latrotoxin-like effects on motor end plates, Annals of Neurology, vol.80, issue.2, pp.189-99, 1999.
DOI : 10.1016/S0165-5728(97)00127-6

B. Jacobs, R. Bullens, O. Hanlon, G. Ang, C. Willison et al., Detection and prevalence of ?-latrotoxin-like effects of serum from patients with Guillain-Barr??? syndrome, Muscle & Nerve, vol.43, issue.4, pp.549-58, 2002.
DOI : 10.1212/WNL.43.2.414

K. Kaida, D. Morita, M. Kanzaki, K. Kamakura, K. Motoyoshi et al., Ganglioside complexes as new target antigens in Guillain-Barr?? syndrome, Annals of Neurology, vol.2, issue.suppl, pp.567-71, 2004.
DOI : 10.1016/S0140-6736(78)92644-2

K. Kaida and S. Kusunoki, Antibodies to gangliosides and ganglioside complexes in Guillain???Barr?? syndrome and Fisher syndrome: Mini-review, Journal of Neuroimmunology, vol.223, issue.1-2, pp.5-12, 2010.
DOI : 10.1016/j.jneuroim.2010.02.001

K. Kaida and S. Kusunoki, Antiganglioside antibodies???Their pathophysiological effects on Guillain-Barr?? Syndrome and variants???, Japanese Journal of Clinical Immunology, vol.34, issue.1, pp.29-39, 2011.
DOI : 10.2177/jsci.34.29

K. Kaida and S. Kusunoki, Immune-mediated neuropathy and anti-glycolipid antibodies, Brain Nerve Shinkei Kenky? No Shinpo, vol.65, pp.413-436, 2013.

M. Koga, M. Gilbert, M. Takahashi, J. Li, S. Koike et al., Enteritis, The Journal of Infectious Diseases, vol.193, issue.4, pp.547-55, 2006.
DOI : 10.1086/499969

P. Godschalk, A. Heikema, M. Gilbert, T. Komagamine, C. Ang et al., The crucial role of Campylobacter jejuni genes in anti-ganglioside antibody induction in Guillain-Barr?? syndrome, Journal of Clinical Investigation, vol.114, issue.11, pp.1659-65, 2004.
DOI : 10.1172/JCI15707DS1

A. Van-belkum, N. Van-den-braak, P. Godschalk, W. Ang, B. Jacobs et al., A Campylobacter jejuni gene associated with immune-mediated neuropathy, Nature Medicine, vol.275, issue.7, pp.752-755, 2001.
DOI : 10.1074/jbc.275.6.3896

M. Kuijf, P. Godschalk, M. Gilbert, H. Endtz, A. Tio-gillen et al., Origin of ganglioside complex antibodies in Guillain???Barr?? syndrome, Journal of Neuroimmunology, vol.188, issue.1-2, pp.69-73, 2007.
DOI : 10.1016/j.jneuroim.2007.05.014

K. Kimoto, M. Koga, M. Odaka, K. Hirata, M. Takahashi et al., Relationship of bacterial strains to clinical syndromes of Campylobacter-associated neuropathies, Neurology, vol.67, issue.10, pp.1837-1880, 2006.
DOI : 10.1212/01.wnl.0000244468.22377.6b

M. Koga, M. Gilbert, J. Li, S. Koike, M. Takahashi et al., Antecedent infections in Fisher syndrome: A common pathogenesis of molecular mimicry, Neurology, vol.64, issue.9, pp.1605-1616, 2005.
DOI : 10.1212/01.WNL.0000160399.08456.7C

N. Yuki, K. Susuki, M. Koga, Y. Nishimoto, M. Odaka et al., Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome, Proceedings of the National Academy of Sciences, vol.52, issue.9, pp.11404-11413, 2004.
DOI : 10.1212/WNL.52.9.1833

B. Jacobs, M. Koga, W. Van-rijs, K. Geleijns, P. Van-doorn et al., Subclass IgG to motor gangliosides related to infection and clinical course in Guillain???Barr?? syndrome, Journal of Neuroimmunology, vol.194, issue.1-2, pp.181-90, 2008.
DOI : 10.1016/j.jneuroim.2007.11.017

N. Yuki, Infectious origins of, and molecular mimicry in, Guillain-Barr?? and Fisher syndromes, The Lancet Infectious Diseases, vol.1, issue.1, pp.29-37, 2001.
DOI : 10.1016/S1473-3099(01)00019-6

J. Spies, K. Westland, J. Bonner, and J. Pollard, Intraneural activated T cells cause focal breakdown of the blood-nerve barrier, Brain, vol.118, issue.4, pp.857-68, 1995.
DOI : 10.1093/brain/118.4.857

G. Harvey and J. Pollard, Peripheral nervous system demyelination from systemic transfer of experimental allergic neuritis serum, Journal of Neuroimmunology, vol.41, issue.2, pp.159-66, 1992.
DOI : 10.1016/0165-5728(92)90066-T

A. Khalili-shirazi, R. Hughes, S. Brostoff, C. Linington, and N. Gregson, T cell responses to myelin proteins in Guillain-Barr?? syndrome, Journal of the Neurological Sciences, vol.111, issue.2, pp.200-203, 1992.
DOI : 10.1016/0022-510X(92)90069-W

M. Adelmann and C. Linington, Molecular mimicry and the autoimmune response to the peripheral nerve myelin PO glycoprotein, Neurochemical Research, vol.23, issue.Suppl, pp.887-91, 1992.
DOI : 10.1007/BF00993264

M. Khattar, W. Chen, and S. Stepkowski, Expanding and converting regulatory T cells: a horizon for immunotherapy, Archivum Immunologiae et Therapiae Experimentalis, vol.178, issue.3, 2009.
DOI : 10.4049/jimmunol.178.4.2018

S. Chiang and E. Ubogu, The role of chemokines in guillain-barr?? syndrome, Muscle & Nerve, vol.8, issue.suppl, pp.320-350, 2013.
DOI : 10.1038/nrd2734

R. Hughes, A. Swan, J. Raphaël, D. Annane, R. Koningsveld et al., Immunotherapy for Guillain-Barre syndrome: a systematic review, Brain, vol.130, issue.9, pp.2245-57, 2007.
DOI : 10.1093/brain/awm004

J. Raphael and S. Chevret, Rational therapy of Guillain-Barré syndrome. The Lancet, p.753, 1998.

G. Hughes, Plasma exchange (plasmapheresis) Agents Actions Suppl, pp.62-67, 1980.

F. Schooneman and A. Gérard, Plasmapheresis in autoimmune syndromes, Indications. Results. Nouv Presse Médicale, vol.11, pp.3847-51, 1982.

K. Gwathmey, R. Balogun, and T. Burns, Neurologic indications for therapeutic plasma exchange: 2013 update, Journal of Clinical Apheresis, vol.77, issue.2, 2014.
DOI : 10.1212/WNL.0b013e31822e55e7

Y. Tagawa, Y. N. Hirata, and K. , The number of plasma exchanges in Guillain-Barré syndrome: evaluation by the removal rate of immunoglobulin G, Rinsh? Shinkeigaku Clin Neurol, vol.38, pp.951-955, 1998.

T. Burnouf, Modern Plasma Fractionation, Transfusion Medicine Reviews, vol.21, issue.2, pp.101-118, 2007.
DOI : 10.1016/j.tmrv.2006.11.001

M. Radosevich and T. Burnouf, Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance, Vox Sanguinis, vol.12, issue.Suppl 15, pp.12-28, 2010.
DOI : 10.1212/WNL.44.2.223

J. Jang, A. Hidalgo, and P. Frenette, Intravenous Immunoglobulins Modulate Neutrophil Activation and Vascular Injury Through Fc??RIII and SHP-1, Circulation Research, vol.110, issue.8, pp.1057-66, 2012.
DOI : 10.1161/CIRCRESAHA.112.266411

R. Kimberly, J. Salmon, J. Bussel, M. Crow, and M. Hilgartner, Modulation of mononuclear phagocyte function by intravenous gamma-globulin, J Immunol Baltim Md, vol.132, pp.745-50, 1950.

E. Van-mirre, J. Teeling, J. Van-der-meer, W. Bleeker, and C. Hack, Monomeric IgG in intravenous Ig preparations is a functional antagonist of FcgammaRII and FcgammaRIIIb, J Immunol Baltim Md, vol.173, pp.332-341, 1950.

J. Abe, T. Jibiki, S. Noma, T. Nakajima, H. Saito et al., Gene Expression Profiling of the Effect of High-Dose Intravenous Ig in Patients with Kawasaki Disease, The Journal of Immunology, vol.174, issue.9, pp.5837-5882, 1950.
DOI : 10.4049/jimmunol.174.9.5837

I. Schwab and F. Nimmerjahn, Intravenous immunoglobulin therapy: how does IgG modulate the immune system?, Nature Reviews Immunology, vol.113, issue.3, pp.176-89, 2013.
DOI : 10.1182/blood-2008-07-166439

M. Aloulou, B. Mkaddem, S. Biarnes-pelicot, M. Boussetta, T. Souchet et al., IgG1 and IVIg induce inhibitory ITAM signaling through Fc??RIII controlling inflammatory responses, Blood, vol.119, issue.13, pp.3084-96, 2012.
DOI : 10.1182/blood-2011-08-376046

URL : http://www.bloodjournal.org/content/bloodjournal/119/13/3084.full.pdf

A. Samuelsson, T. Towers, and J. Ravetch, Anti-inflammatory Activity of IVIG Mediated Through the Inhibitory Fc Receptor, Science, vol.291, issue.5503, pp.484-490, 2001.
DOI : 10.1126/science.291.5503.484

R. Anthony, F. Wermeling, M. Karlsson, and J. Ravetch, Identification of a receptor required for the anti-inflammatory activity of IVIG, Proceedings of the National Academy of Sciences, vol.8, issue.6, 2008.
DOI : 10.1038/ni1470

A. Boruchov, G. Heller, M. Veri, E. Bonvini, J. Ravetch et al., Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions, Journal of Clinical Investigation, vol.115, issue.10, pp.2914-2937, 2005.
DOI : 10.1172/JCI24772

D. Roopenian and S. Akilesh, FcRn: the neonatal Fc receptor comes of age, Nature Reviews Immunology, vol.100, issue.9, pp.715-740, 2007.
DOI : 10.4049/jimmunol.178.8.5390

T. Suzuki, A. Ishii-watabe, M. Tada, T. Kobayashi, T. Kanayasu-toyoda et al., Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR, The Journal of Immunology, vol.184, issue.4, 1950.
DOI : 10.4049/jimmunol.0903296

C. Magdelaine-beuzelin, M. Ohresser, and H. Watier, FcRn, un r??cepteur d???IgG aux multiples facettes, m??decine/sciences, vol.25, issue.12, pp.1053-1059, 2009.
DOI : 10.1051/medsci/200925121053

URL : http://www.medecinesciences.org/articles/medsci/pdf/2009/12/medsci20092512p1053.pdf

F. Dekeyser, H. Dekeyser, M. Kazatchkine, F. Rossi, H. Dang et al., Pooled human immunoglobulins contain anti-idiotypes with reactivity against the SLE-associated 4B4 crossreactive idiotype, Clin Exp Rheumatol, vol.14, pp.587-91, 1996.

P. Lopez, F. Irazoqui, and G. Nores, Normal human plasma contains antibodies that specifically block neuropathy-associated human anti-GM1 IgG-antibodies, Journal of Neuroimmunology, vol.105, issue.2, pp.179-83, 2000.
DOI : 10.1016/S0165-5728(99)00276-3

Y. Shoenfeld, L. Rauova, B. Gilburd, F. Kvapil, I. Goldberg et al., Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus, International Immunology, vol.14, issue.11, pp.1303-1314, 2002.
DOI : 10.1093/intimm/dxf099

A. Kessel, H. Ammuri, R. Peri, E. Pavlotzky, M. Blank et al., Intravenous Immunoglobulin Therapy Affects T Regulatory Cells by Increasing Their Suppressive Function, The Journal of Immunology, vol.179, issue.8, pp.5571-5576, 1950.
DOI : 10.4049/jimmunol.179.8.5571

S. Lee, Y. Jung, J. Ryu, C. Kang, E. Kim et al., Intravenous Immunoglobulin Attenuates Experimental Autoimmune Arthritis by Inducing Reciprocal Regulation of Th17 and Treg Cells in an Interleukin-10-Dependent Manner, Arthritis & Rheumatology, vol.38, issue.Suppl 1, pp.1768-78, 2014.
DOI : 10.1002/eji.200838331

A. Tjon, T. Tha-in, H. Metselaar, R. Van-gent, L. Van-der-laan et al., Patients treated with high-dose intravenous immunoglobulin show selective activation of regulatory T cells, Clinical & Experimental Immunology, vol.112, issue.1 Suppl. 57, pp.259-67, 2013.
DOI : 10.1182/blood-2008-02-138073

A. Ephrem, S. Chamat, C. Miquel, S. Fisson, L. Mouthon et al., Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis, Blood, vol.111, issue.2, pp.715-737, 2008.
DOI : 10.1182/blood-2007-03-079947

H. Lutz and P. Späth, Anti-Inflammatory Effect of Intravenous Immunoglobulin Mediated Through Modulation of Complement Activation, Clinical Reviews in Allergy & Immunology, vol.29, issue.3, pp.207-219, 2005.
DOI : 10.1385/CRIAI:29:3:207

S. Konrad, U. Baumann, R. Schmidt, and J. Gessner, Intravenous immunoglobulin (IVIG)-mediated neutralisation of C5a: a direct mechanism of IVIG in the maintenance of a high FcgammaRIIB to FcgammaRIII expression ratio on macrophages, British Journal of Haematology, vol.174, issue.3, pp.345-352, 2006.
DOI : 10.4049/jimmunol.174.5.3041

F. Van-der-meché and P. Schmitz, A Randomized Trial Comparing Intravenous Immune Globulin and Plasma Exchange in Guillain-Barr?? Syndrome, New England Journal of Medicine, vol.326, issue.17, pp.1123-1132, 1992.
DOI : 10.1056/NEJM199204233261705

R. Kleyweg and F. Van-der-meché, Guillain-Barré disease: a current treatment method using immunoglobulins, Ned Tijdschr Geneeskd, vol.136, 1992.

R. Korinthenberg, J. Schessl, J. Kirschner, and J. Mönting, Intravenously Administered Immunoglobulin in the Treatment of Childhood Guillain-Barre Syndrome: A Randomized Trial, PEDIATRICS, vol.116, issue.1, pp.8-14, 2005.
DOI : 10.1542/peds.2004-1324

U. Katz, A. Achiron, Y. Sherer, and Y. Shoenfeld, Safety of intravenous immunoglobulin (IVIG) therapy, Autoimmunity Reviews, vol.6, issue.4, pp.257-266, 2007.
DOI : 10.1016/j.autrev.2006.08.011

R. Horch, H. Gerngross, W. Lang, P. Mauckner, D. Nord et al., Indications and safety aspects of vacuum-assisted wound closure, MMW Fortschr Med, vol.147, pp.1-5, 2005.

F. Fakhouri, Intravenous immunoglobulins and acute renal failure: mechanism and prevention. Rev Médecine Interne Fondée Par Société Natl Francaise Médecine Interne, pp.4-6, 2007.

S. Chapman, K. Gilkerson, T. Davin, and M. Pritzker, Acute Renal Failure and Intravenous Immune Globulin: Occurs with Sucrose-Stabilized, but Not with D-Sorbitol???Stabilized, Formulation, Annals of Pharmacotherapy, vol.19, issue.1, pp.2059-67, 2004.
DOI : 10.1159/000179925

E. Daphnis, K. Stylianou, M. Alexandrakis, I. Xylouri, E. Vardaki et al., Acute Renal Failure, Translocational Hyponatremia and Hyperkalemia following Intravenous Immunoglobulin Therapy, Nephron Clinical Practice, vol.106, issue.4, pp.143-151, 2007.
DOI : 10.1001/archinte.1942.00200160121010

R. Ameratunga, J. Sinclair, and J. Kolbe, Increased risk of adverse events when changing intravenous immunoglobulin preparations, Clinical & Experimental Immunology, vol.74, issue.Suppl. 15, pp.111-114, 2004.
DOI : 10.1067/mai.2002.129359

I. Marie, G. Maurey, F. Hervé, M. Hellot, and H. Levesque, Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature, British Journal of Dermatology, vol.46, issue.4, pp.714-735, 2006.
DOI : 10.1212/WNL.46.1.250

M. Berger, Adverse Effects of IgG Therapy, The Journal of Allergy and Clinical Immunology: In Practice, vol.1, issue.6, pp.558-66, 2013.
DOI : 10.1016/j.jaip.2013.09.012

E. Stiehm, Adverse Effects of Human Immunoglobulin Therapy, Transfusion Medicine Reviews, vol.27, issue.3, pp.171-179, 2013.
DOI : 10.1016/j.tmrv.2013.05.004

W. Sewell, J. Kerr, M. Behr-gross, and H. Peter, European consensus proposal for immunoglobulin therapies, European Journal of Immunology, vol.23, issue.Suppl. 1, 2014.
DOI : 10.1097/BOR.0b013e3283412fd4

. Guillainbarresyndromesteroidtr, Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome, The Lancet [Internet]. mars, vol.341, 1993.

R. Hughes and P. Van-doorn, Corticosteroids for Guillain-Barré syndrome, Cochrane Database Syst Rev, vol.8, 2012.

R. Van-koningsveld, P. Schmitz, F. Meché, L. Visser, J. Meulstee et al., Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barr?? syndrome: randomised trial, The Lancet, vol.363, issue.9404, pp.192-198, 2004.
DOI : 10.1016/S0140-6736(03)15324-X

M. Rich and M. Pinter, Sodium channel inactivation in an animal model of acute quadriplegic myopathy, Annals of Neurology, vol.78, issue.1, pp.26-33, 2001.
DOI : 10.1016/S0306-4522(96)00624-0

M. Rich, M. Pinter, S. Kraner, and R. Barchi, Loss of electrical excitability in an animal model of acute quadriplegic myopathy, Annals of Neurology, vol.14, issue.2, pp.171-180, 1998.
DOI : 10.1001/archneur.1972.00490080099012

M. Garssen, R. Van-koningsveld, P. Van-doorn, I. Merkies, M. Scheltens-de-boer et al., Treatment of Guillain Barre syndrome with mycophenolate mofetil: a pilot study, Journal of Neurology, Neurosurgery & Psychiatry, vol.78, issue.9, pp.1012-1015, 2007.
DOI : 10.1136/jnnp.2006.102731

S. Halstead, F. Zitman, P. Humphreys, K. Greenshields, J. Verschuuren et al., Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model, Brain, vol.1, issue.5, pp.1197-208, 2008.
DOI : 10.1016/S1473-3099(01)00019-6

R. Hughes, A. Swan, and P. Van-doorn, Intravenous immunoglobulin for Guillain-Barré syndrome, Cochrane Database Syst Rev, vol.7, 2012.

J. Winters, D. Brown, E. Hazard, A. Chainani, and C. Andrzejewski, Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barr?? syndrome, BMC Health Services Research, vol.71, issue.Suppl 4, p.101, 2011.
DOI : 10.1212/01.wnl.0000316393.54258.d1

R. Hughes, J. Raphaël, A. Swan, and P. Van-doorn, Intravenous immunoglobulin for Guillain- Barré syndrome, Cochrane Database Syst Rev, issue.2, 2001.
DOI : 10.1002/14651858.cd002063.pub5

URL : http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002063.pub5/pdf/abstract

M. Dada and A. Kaplan, Plasmapheresis treatment in Guillain-Barré syndrome: potential benefit over IVIg in patients with axonal involvement. Ther Apher Dial Off Peer-Rev J, pp.409-421, 2004.

M. Mori, S. Kuwabara, T. Fukutake, and T. Hattori, Intravenous immunoglobulin therapy for Miller Fisher syndrome, Neurology, vol.68, issue.14, pp.1144-1150, 2007.
DOI : 10.1212/01.wnl.0000258673.31824.61

R. Hughes, J. Pritchard, and R. Hadden, Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome, Cochrane Database Syst Rev, vol.2, 2013.

M. Oczko-walker, G. Manousakis, S. Wang, J. Malter, and A. Waclawik, Plasma Exchange After Initial Intravenous Immunoglobulin Treatment in Guillain-Barr?? Syndrome: Critical Reassessment of Effectiveness and Cost-Efficiency, Journal of Clinical Neuromuscular Disease, vol.12, issue.2, pp.55-61, 2010.
DOI : 10.1097/CND.0b013e3181f3dbbf

P. Farcas, L. Avnun, S. Frisher, Y. Herishanu, and I. Wirguin, Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barr?? syndrome, The Lancet, vol.350, issue.9093, p.1747, 1997.
DOI : 10.1016/S0140-6736(97)24050-X

R. Hughes, A. Swan, and P. Van-doorn, Intravenous immunoglobulin for Guillain-Barré syndrome, Cochrane Database Syst Rev, vol.9, 2014.

R. Kleyweg and F. Van-der-meche, Treatment related fluctuations in Guillain-Barre syndrome after high-dose immunoglobulins or plasma-exchange., Journal of Neurology, Neurosurgery & Psychiatry, vol.54, issue.11, pp.957-60, 1991.
DOI : 10.1136/jnnp.54.11.957

R. Hughes, E. Sanders, S. Hall, P. Atkinson, A. Colchester et al., Subacute Idiopathic Demyelinating Polyradiculoneuropathy, Archives of Neurology, vol.49, issue.6, pp.612-618, 1992.
DOI : 10.1001/archneur.1992.00530300044009

L. Ruts, J. Drenthen, B. Jacobs, P. Van-doorn, G. Dutch et al., Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: A prospective study, Neurology, vol.74, issue.21, pp.1680-1686, 2010.
DOI : 10.1212/WNL.0b013e3181e07d14

M. Odaka, Y. N. Hirata, and K. , Patients with chronic inflammatory demyelinating polyneuropathy initially diagnosed as Guillain-Barr??? syndrome, Journal of Neurology, vol.250, issue.8, pp.913-919, 2003.
DOI : 10.1007/s00415-003-1096-y

K. Kuitwaard, J. De-gelder, A. Tio-gillen, W. Hop, T. Van-gelder et al., Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barr???? syndrome, Annals of Neurology, vol.35, issue.5, pp.597-603, 2009.
DOI : 10.1212/WNL.35.8.1096

R. Hughes, E. Wijdicks, E. Benson, D. Cornblath, A. Hahn et al., Supportive Care for Patients With Guillain-Barr?? Syndrome, Archives of Neurology, vol.62, issue.8, pp.1194-1202, 2005.
DOI : 10.1001/archneur.62.8.1194

P. Flachenecker, K. Lem, W. Müllges, and K. Reiners, Detection of serious bradyarrhythmias in Guillain-Barr?? syndrome: Sensitivity and specificity of the 24-hour heart rate power spectrum, Clinical Autonomic Research, vol.97, issue.4, pp.185-91, 2000.
DOI : 10.1161/01.CIR.97.20.2031

A. Ueda, K. Asakura, T. Mihara, H. Hara, M. Ueda et al., Acute Autonomic, Sensory and Motor Neuropathy: Successful Treatment with IVIg, Internal Medicine, vol.48, issue.10, pp.843-849, 2009.
DOI : 10.2169/internalmedicine.48.1848

M. Ali and R. Hutfluss, Epidural fentanyl-bupivacaine infusion for management of pain in the Guillain-Barré syndrome, Reg Anesth, vol.17, pp.171-175, 1992.

M. Connelly, J. Shagrin, and C. Warfield, Epidural Opioids for the Management of Pain in a Patient with the Guillain-Barr?? Syndrome, Anesthesiology, vol.72, issue.2, pp.381-384, 1990.
DOI : 10.1097/00000542-199002000-00026

B. Rosenfeld, C. Borel, and D. Hanley, Epidural Morphine Treatment of Pain in Guillain-Barre Syndrome, Archives of Neurology, vol.43, issue.11, pp.1194-1200, 1986.
DOI : 10.1001/archneur.1986.00520110080023

C. Pandey, M. Raza, M. Tripathi, D. Navkar, A. Kumar et al., The Comparative Evaluation of Gabapentin and Carbamazepine for Pain Management in Guillain-Barr?? Syndrome Patients in the Intensive Care Unit, Anesthesia & Analgesia, vol.101, issue.1, pp.220-225, 2005.
DOI : 10.1213/01.ANE.0000152186.89020.36

M. Tripathi and S. Kaushik, Carbamezapine for pain management in Guillain-Barr?? syndrome patients in the intensive care unit, Critical Care Medicine, vol.28, issue.3, pp.655-663, 2000.
DOI : 10.1097/00003246-200003000-00009

C. Pandey, N. Bose, G. Garg, N. Singh, A. Baronia et al., Gabapentin for the Treatment of Pain in Guillain-Barr?? Syndrome: A Double-Blinded, Placebo-Controlled, Crossover Study, Anesthesia & Analgesia, vol.95, issue.6, pp.1719-1742, 2002.
DOI : 10.1097/00000539-200212000-00046

R. Kabore, L. Magy, S. Boukhris, T. Mabrouk, M. Lacoste et al., Inter??t de la corticoth??rapie dans le traitement de la douleur ?? la phase aigu?? du syndrome de Guillain-Barr??, Revue Neurologique, vol.160, issue.8-9, pp.821-824, 2004.
DOI : 10.1016/S0035-3787(04)71037-1

F. Khan, Rehabilitation in Guillian Barre syndrome, Aust Fam Physician, vol.33, pp.1013-1020, 2004.

F. Khan, L. Ng, B. Amatya, C. Brand, and L. Turner-stokes, Multidisciplinary care for Guillain-Barré syndrome. Cochrane Database Syst Rev, 2010.

F. Khan and B. Amatya, Rehabilitation interventions in patients with acute demyelinating inflammatory polyneuropathy: a systematic review, Eur J Phys Rehabil Med, vol.48, pp.507-529, 2012.

M. Garssen, R. Van-koningsveld, and P. Van-doorn, Residual fatigue is independent of antecedent events and disease severity in Guillain-Barr?? syndrome, Journal of Neurology, vol.54, issue.8, pp.1143-1149, 2006.
DOI : 10.1212/WNL.54.3.620

I. Merkies and C. Faber, Fatigue in immune-mediated neuropathies, Neuromuscular Disorders, vol.22, pp.203-210, 2012.
DOI : 10.1016/j.nmd.2012.10.014

A. Forsberg, R. Press, U. Einarsson, J. De-pedro-cuesta, and L. Holmqvist, Disability and health-related quality of life in Guillain-Barr?? syndrome during the first two years after onset: a prospective study, Clinical Rehabilitation, vol.17, issue.8, pp.900-909, 2005.
DOI : 10.1212/WNL.59.1.84

S. Darweesh, S. Polinder, M. Mulder, C. Baena, N. Van-leeuwen et al., Health-related quality of life in Guillain-Barr?? syndrome patients: a systematic review, Journal of the Peripheral Nervous System, vol.366, issue.1, pp.24-35, 2014.
DOI : 10.1056/NEJMra1114525

M. Garssen, P. Van-doorn, and G. Visser, Nerve conduction studies in relation to residual fatigue in Guillain-Barr?? syndrome, Journal of Neurology, vol.45, issue.7, pp.851-857, 2006.
DOI : 10.1212/WNL.18.12.1143

M. Garssen, J. Blok, P. Van-doorn, and G. Visser, Conduction velocity distribution in neurologically well-recovered but fatigued Guillain???Barr?? syndrome patients, Muscle & Nerve, vol.187, issue.2, pp.177-82, 2006.
DOI : 10.1212/WNL.53.8.1648

M. Garssen, M. Schillings, P. Van-doorn, B. Van-engelen, and M. Zwarts, Contribution of central and peripheral factors to residual fatigue in Guillain???Barr?? syndrome, Muscle & Nerve, vol.95, issue.1, pp.93-102, 2007.
DOI : 10.1212/01.WNL.0000081049.14098.50

R. Graham, R. A. Hughes, and C. White, A prospective study of physiotherapist prescribed community based exercise in inflammatory peripheral neuropathy, Journal of Neurology, vol.87, issue.2, pp.228-263, 2007.
DOI : 10.1136/bmj.314.7094.1580

J. Bussmann, M. Garssen, P. Van-doorn, and H. Stam, Analysing the favourable effects of physical exercise: relationships between physical fitness, fatigue and functioning in Guillain-Barr?? syndrome and chronic inflammatory demyelinating polyneuropathy, Journal of Rehabilitation Medicine, vol.39, issue.2, pp.121-126, 2007.
DOI : 10.2340/16501977-0007

M. Garssen, J. Bussmann, P. Schmitz, A. Zandbergen, T. Welter et al., Physical training and fatigue, fitness, and quality of life in Guillain-Barre syndrome and CIDP, Neurology, vol.63, issue.12, pp.2393-2398, 2004.
DOI : 10.1212/01.WNL.0000148589.87107.9C

F. Khan, J. Pallant, B. Amatya, L. Ng, A. Gorelik et al., Outcomes of high- and low-intensity rehabilitation programme for persons in chronic phase after Guillain-Barr?? syndrome: A randomized controlled trial, Journal of Rehabilitation Medicine, vol.43, issue.7, pp.638-684, 2011.
DOI : 10.2340/16501977-0826

F. Fourrier, L. Robriquet, J. Hurtevent, and S. Spagnolo, A simple functional marker to predict the need for prolonged mechanical ventilation in patients with Guillain-Barr?? syndrome, Critical Care, vol.15, issue.1, p.65, 2011.
DOI : 10.1097/01.CCM.0000186898.58709.AA

D. Orlikowski, H. Prigent, J. Raphaël, and T. Sharshar, L'insuffisance respiratoire aigu?? du syndrome de Guillain-Barr?? et de la myasth??nie auto-immune. De la d??tection au sevrage de la ventilation m??canique, R??animation, vol.14, issue.2, pp.118-143, 2005.
DOI : 10.1016/j.reaurg.2004.10.016

C. Walgaard, H. Lingsma, L. Ruts, J. Drenthen, R. Van-koningsveld et al., Prediction of respiratory insufficiency in Guillain-Barr?? syndrome, Annals of Neurology, vol.67, pp.781-788, 2010.
DOI : 10.1002/ana.21976

J. Chevrolet and P. Deléamont, Repeated Vital Capacity Measurements as Predictive Parameters for Mechanical Ventilation Need and Weaning Success in the Guillain-Barr?? Syndrome, American Review of Respiratory Disease, vol.142, issue.4, pp.814-822, 1991.
DOI : 10.1056/NEJM198603203141209

N. Lawn, D. Fletcher, R. Henderson, T. Wolter, and E. Wijdicks, Anticipating Mechanical Ventilation in Guillain-Barr?? Syndrome, Archives of Neurology, vol.58, issue.6, pp.893-901, 2001.
DOI : 10.1001/archneur.58.6.893

N. Lawn and E. Wijdicks, Tracheostomy in Guillain-Barr??? syndrome, Muscle & Nerve, vol.60, issue.8, pp.1058-62, 1999.
DOI : 10.1212/WNL.35.8.1096

A. Mathieu, A. Guillon, S. Leyre, F. Martin, J. Fusciardi et al., Aerosolized Lidocaine During Invasive Mechanical Ventilation, Journal of Neurosurgical Anesthesiology, vol.25, issue.1, pp.8-15, 2013.
DOI : 10.1097/ANA.0b013e31826a75b1

D. Gracey, J. Mcmichan, M. Divertie, and F. Howard, Respiratory failure in Guillain-Barré syndrome: a 6-year experience, Mayo Clin Proc, vol.57, pp.742-748, 1982.

A. Ropper and S. Kehne, Guillain-Barre syndrome: Management of respiratory failure, Neurology, vol.35, issue.11, pp.1662-1667, 1985.
DOI : 10.1212/WNL.35.11.1662

M. Tramèr, R. Moore, and H. Mcquay, Propofol and bradycardia: causation, frequency and severity, British Journal of Anaesthesia, vol.78, issue.6, pp.642-51, 1997.
DOI : 10.1093/bja/78.6.642

K. Saifudheen, J. Jose, V. Gafoor, and M. Musthafa, Guillain-Barre syndrome and SIADH, Neurology, vol.76, issue.8, pp.701-705, 2011.
DOI : 10.1212/WNL.0b013e31820d8b40

P. Terragni, M. Antonelli, R. Fumagalli, C. Faggiano, M. Berardino et al., Early vs Late Tracheotomy for Prevention of Pneumonia in Mechanically Ventilated Adult ICU Patients, JAMA, vol.303, issue.15, pp.1483-1492, 2010.
DOI : 10.1001/jama.2010.447

J. Trouillet, C. Luyt, M. Guiguet, A. Ouattara, E. Vaissier et al., Early Percutaneous Tracheotomy Versus Prolonged Intubation of Mechanically Ventilated Patients After Cardiac Surgery, Annals of Internal Medicine, vol.154, issue.6, pp.373-83, 2011.
DOI : 10.7326/0003-4819-154-6-201103150-00002

F. Wang, Y. Wu, L. Bo, J. Lou, J. Zhu et al., The Timing of Tracheotomy in Critically Ill Patients Undergoing Mechanical Ventilation, Chest, vol.140, issue.6, pp.1456-65, 2011.
DOI : 10.1378/chest.11-2024

M. Köhrmann, H. Huttner, T. Nowe, P. Schellinger, and S. Schwab, Mechanical Ventilation in Guillain-Barr?? Syndrome: Does Age Influence Functional Outcome?, European Neurology, vol.61, issue.6, pp.358-63, 2009.
DOI : 10.1159/000210548

S. Blot, D. Koulenti, G. Dimopoulos, C. Martin, A. Komnos et al., Prevalence, Risk Factors, and Mortality for Ventilator-Associated Pneumonia in Middle-Aged, Old, and Very Old Critically Ill Patients*, Critical Care Medicine, vol.42, issue.3, pp.601-610, 2014.
DOI : 10.1097/01.ccm.0000435665.07446.50